Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

Core Insights - Minerva Neurosciences, Inc. is hosting a virtual KOL event on February 3, 2026, to discuss the challenges of treating negative symptoms of schizophrenia and the upcoming Phase 3 trial of roluperidone [1][2] Company Overview - Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly targeting negative symptoms of schizophrenia with its product candidate roluperidone [9] Industry Context - Current antipsychotics do not adequately address negative symptoms of schizophrenia, which affects 50% to 60% of individuals with the disorder, highlighting an unmet medical need [2][8] - The FDA has recognized the lack of approved treatments specifically for negative symptoms and held a public meeting in August 2024 to discuss optimal clinical trial approaches [2][8] Expert Contributions - Gregory Strauss, PhD, and Brian Kirkpatrick, MD, MSPH, will provide insights during the KOL event, focusing on the patient burden of negative symptoms and the regulatory challenges in assessing these symptoms [1][4][5]